

1694
PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Schrimpf, *et al.*

Serial No.: 09/833,914

Filed: April 12, 2001

For: DIAZABICYCLIC CENTRAL
NERVOUS SYSTEM ACTIVE
AGENTS

Examiner: B. L. Coleman

Group Art Unit: 1624

Case No.: 6696.US.O2

Commissioner for Patents
Washington D.C. 20231CERTIFICATE OF MAILING (37 CFR
1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: September 23, 2002

Tanya Parent 9/23/02
Tanya Parent Date

TECH CENTER 1600/2900

OCT 07 2002

RECEIVED

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS are the following:

1. Response to Restriction Requirement (2 Pages);
2. Request for Two-Month Extension of Time, in duplicate; and
3. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.



23492

ABBOTT LABORATORIES
Telephone: (847) 937-8272
Facsimile: (847) 938-2623Respectfully submitted,
Schrimpf, *et al.*

Portia Chen
Portia Chen
Registration No. 44,075
Attorney for Applicants